BGLAP and cancer: While multiplex technologies possess high sensitivity, which is key to discovering clinically relevant proteins that are present at extremely low concentrations in the plasma/serum, there may be a concern for missing highly abundant tumor-derived proteins, such as CA125 for OC, which increase by several orders of magnitude in cancer plasma/serum.